Correspondingly, constitutive receptor tyrosine kinase (RTK) pathway activity is prevalent in many cancer types, mainly due to activating mutations in the constituents of the RAS-RAF-MEK axis [68,69]. This evidence concerns the gene MAP2K7 and cancer.